Yoko Kawamoto

Learn More
BACKGROUND KRAS mutations are predictive markers for the efficacy of anti-EGFR antibody therapies in patients with metastatic colorectal cancer. Although the mutational status of KRAS is reportedly highly concordant between primary and metastatic lesions, it is not yet clear whether genotoxic chemotherapies might induce additional mutations. METHODS A(More)
Nestin, a class VI intermediate filament protein, is expressed by neuronal progenitor cells in the subventricular zone (SVZ). In the present study, we analyzed the nestin expression and phosphorylation levels in nerve cells in a mouse model of cerebral ischemia and reperfusion. C57BL/6 mice were subjected to three-vessel occlusion for 14 min, and were(More)
Sir, We appreciate the comment from Dr Vauthey and colleagues (Vauthey et al, 2012) on our recently published article by Kawamoto et al (2012) titled 'KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer'. The KRAS mutation has been regarded as one of the major 'driver mutations' of colorectal cancer, and its(More)
  • 1